Ocugen (OCGN) Return on Capital Employed (2015 - 2026)
Ocugen (OCGN) posted Return on Capital Employed of 224.57% for Q1 2026, up 1.8% on a QoQ basis from 228.68% in Q4 2025, and down 12373.0% year-over-year from N/an in Q1 2025.
Ocugen (OCGN) Return on Capital Employed (2015 - 2026) Analysis & Trends
Ocugen's Return on Capital Employed history runs 12 years deep, the most recent figure standing at 224.57% for Q1 2026.
- Quarterly Return on Capital Employed fell 12373.0% year-over-year to 224.57% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 224.57% (down 12373.0% YoY) and the FY2025 annual result came in at 157.54%, down 5205.0% from the prior year.
- Return on Capital Employed was 224.57% for Q1 2026 at Ocugen, up from 228.68% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 55.93% in Q2 2022 and bottomed at 228.68% in Q4 2025.
- A 5-year average of 132.0% and a median of 124.75% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2025 — Return on Capital Employed soared 4811 bps — and 2026, when it tumbled 12373 bps.
- Ocugen's Return on Capital Employed stood at 106.16% in 2022, then decreased by 18 bps to 124.75% in 2023, then increased by 13 bps to 108.21% in 2024, then plunged by 111 bps to 228.68% in 2025, then climbed by 2 bps to 224.57% in 2026.
- Business Quant data shows OCGN's Return on Capital Employed at 224.57% in Q1 2026, 228.68% in Q4 2025, and 169.61% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Ocugen | 63.79 Mn | 63.79 Mn | - | -224.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -224.57% |
| Dec 31, 2025 | -228.68% |
| Sep 30, 2025 | -169.61% |
| Jun 30, 2025 | -134.97% |
| Mar 31, 2025 | -100.84% |
| Dec 31, 2024 | -108.21% |
| Sep 30, 2024 | -147.82% |
| Jun 30, 2024 | -183.08% |
| Mar 31, 2024 | -141.76% |
| Dec 31, 2023 | -124.75% |
| Sep 30, 2023 | -124.57% |
| Jun 30, 2023 | -132.14% |
| Mar 31, 2023 | -116.07% |
| Dec 31, 2022 | -106.16% |
| Sep 30, 2022 | -81.39% |
| Jun 30, 2022 | -55.93% |
| Mar 31, 2022 | -63.38% |
| Dec 31, 2021 | -55.78% |
| Sep 30, 2021 | -41.44% |
| Jun 30, 2021 | -55.41% |